ReviewInternational journal of molecular sciences2018
Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.Cancer science · 2025Article
- Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Prognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients.World journal of surgical oncology · 2022Article
- Molecular Pathology of Lung Cancer.Cold Spring Harbor perspectives in medicine · 2022Review
- Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach.International journal of molecular sciences · 2021Review
- Review
- Malignant Pleural Mesothelioma: Time Is Running Out.Journal of clinical medicine · 2021Article
- COL1A1 Is a Potential Prognostic Biomarker and Correlated with Immune Infiltration in Mesothelioma.BioMed research international · 2021Article
- A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma.EBioMedicine · 2020Article
- Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.Turk gogus kalp damar cerrahisi dergisi · 2020Article
- Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma.Journal of thoracic disease · 2019Article
- Special Issue on Mechanisms of Mesothelioma Heterogeneity: Highlights and Open Questions.International journal of molecular sciences · 2018Article
- Biomarkers in malignant pleural mesothelioma: current status and future directions.Journal of thoracic disease · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant pleural mesothelioma (MPM) tumors are remarkably aggressive and most patients only survive for 5-12 months; irrespective of stage; after primary symptoms appear. Compounding matters is that MPM remains unresponsive to conventional standards of care; including radiation and chemotherapy. Currently; instead of relying on molecular signatures and histological typing; MPM treatment options are guided by clinical stage and patient characteristics because the mechanism of carcinogenesis has not been fully elucidated; although about 80% of cases can be linked to asbestos exposure. Several molecular pathways have been implicated in the MPM tumor microenvironment; such as angiogenesis; apoptosis; cell-cycle regulation and several growth factor-related pathways predicted to be amenable to therapeutic intervention. Furthermore, the availability of genomic data has improved our understanding of the pathobiology of MPM. The MPM genomic landscape is dominated by inactivating mutations in several tumor suppressor genes; such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.